Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin effect on glucose tolerance in MTNR1B variant carriers
NCT01705639Phase 3Completed
- Sponsor
- University of Helsinki
- Start
- Nov 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of melatonin in impaired glucose tolerance (IGT), sponsored by University of Helsinki. Primary endpoint: Glucose tolerance at 3 months. Started Nov 2012; status: completed.
02
Drugs
melatonin
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT01705639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01705639.